Valiant Organics Ltd

Director/MD changes

• Nemin M. Savadia re-appointed as Executive Director; not debarred; not related to other directors; effective Sept 29, 2026.
• Santosh S. Vora re-appointed as Non-Executive Director; not debarred; not related to other directors; effective Sept 29, 2026.
• Sathiababu K. Kallada re-appointed as Managing Director from May 24, 2027 to May 23, 2030; not debarred.

AGM Details

• AGM held 29 Sep 2026 at 11:30 IST via VC/OAVM.

Voting & Record Dates

• Remote e-voting 25–28 Sep 2026; record date 22 Sep 2026; 39,249 shareholders on record.

Attendance

• Meeting attended via VC/OAVM; 51 attendees (7 promoters, 44 public).

Resolutions & Outcomes

• Resolution 1: Adoption of financial statements; passed.
• Resolution 2: Re-appointment Nemin M. Savadia; passed.
• Resolution 3: Re-appointment Santosh S. Vora; passed.
• Resolution 4: Ratify cost auditor remuneration; passed.
• Resolution 5: Shifting Registered Office within Maharashtra; passed.
• Resolution 6: Revision in MD terms for Sathiababu K. Kallada; passed.
• Resolution 7: Re-appointment of MD Sathiababu K. Kallada; passed.
• Resolution 8: Revision in ED terms for Mahek M. Chheda; passed.
• Resolution 9: Revision in ED terms for Nemin M. Savadia; passed.
• Resolution 10: Revision in ED terms for Siddharth D. Shah; passed.
• Resolution 11: Material Related Party Transaction with Aarti Industries; passed.
• Resolution 12: Material Related Party Transaction with Valiant Laboratories; passed.
• Resolution 13: Material Related Party Transaction with Alchemie Speciality Chemicals; passed.
• Resolution 14: Material Related Party Transaction with Valiant Advanced Sciences; passed.
• Resolution 15: Other related party transactions; passed.

Director Changes & Appointments

• MD/ED appointments and revisions: Kallada, Chheda, Savadia, Shah; all resolutions passed.

Auditors

• Cost Auditor remuneration for FY 2026-27 ratified.

Business Overview

• Valiant Organics manufactures specialty chemicals including chlorophenol derivatives and benzene derivatives.
• Products span PNA, PAP, and pharma intermediates with diversified pharma, dyes, pigments, and agrochemicals clients.
• AGM presentation highlights the company's manufacturing focus and multi-location footprint.

Manufacturing Footprint & Capacity

• Six manufacturing units across five locations, total capacity 80,000 TPA.
• Five zero-liquid-discharge plants are operated by the company.

Financial Snapshot

• Market capitalization around INR 567 crore as of 31 March 2026.

AGM Details

• AGM held on Sep 29, 2026 at 11:30 IST via VC/OAVM.
• Voting eligibility cut-off: Sep 22, 2026.
• Remote e-voting period: Sep 25–28, 2026.
• AGM concluded at 12:09 IST.

Ordinary Business

• Adoption of audited standalone and Consolidated financial statements for the year.
• Re-appointment of Nemin M. Savadia on rotation.
• Re-appointment of Santosh S. Vora on rotation.

Special Business

• Ratification of cost auditor remuneration for 2026-27.
• Shift of registered office within Maharashtra; MOA amendment.
• Revision in MD terms for Sathiababu K. Kallada.
• Re-appointment of Sathiababu K. Kallada as MD.
• Revision in terms for Mahek M. Chheda, ED.
• Revision in terms for Nemin M. Savadia, ED.
• Revision in terms for Siddharth D. Shah, ED.
• Approval of RPT with Aarti Industries Limited.
• Approval of RPT with Valiant Laboratories Limited.
• Approval of RPT with Alchemie Speciality Chemicals Private Limited.
• Approval of RPT with Valiant Advanced Sciences Private Limited.
• Approval of RPT with Alchemie Finechem Private Limited.

Voting Results

• Consolidated voting results to be submitted to exchanges; actual results not disclosed.

Governance Details

• Scrutinizer appointed for e-voting and fair conduct of proceedings.

Valiant Organics Ltd — Trading Window closed from Thursday, October 01, 2026 until the expiry of 48 hours after the declaration of Financial Results for the quarter and half year ended September 30, 2026

Business Overview

• Valiant Organics manufactures specialty chemicals, including chlorophenol and benzene derivatives.
• Six units across five locations with total capacity of 70,000 TPA.
• Diversified client base across dyes, pigments, agrochemicals, pharmaceuticals, and veterinary products.
• Q1-FY27 highlights margin expansion and raw-material efficiency.

Operational Highlights

• Q1-FY27 consolidated revenue rose 13.3% YoY to INR 2,315 Mn.
• Gross margin improved to 43% from 39% YoY.
• Raw material cost declined to 57% of sales, saving ~INR 4 per INR 100 revenue.
• EBITDA margin expanded to 17.97%, highest in six quarters.
• PAT at INR 293 Mn; PAT margin 12.66%.
• Finance cost declined 15% YoY to INR 51 Mn.

Financial Performance

• Consolidated Q1-FY27 revenue INR 2,315 Mn; EBITDA INR 416 Mn; PBT INR 368 Mn; PAT INR 293 Mn.
• EBITDA margin 17.97%, PAT margin 12.66%.
• Standalone Q1-FY27 revenue INR 2,315 Mn; EBITDA INR 416 Mn; PAT INR 218 Mn; PBT INR 289 Mn.
• Standalone PAT margin 9.42%; consolidated EPS INR 10.44; standalone EPS INR 7.79.

Capital Structure & Liquidity

• Equity: INR 7,594 Mn; borrowings: INR 2,527 Mn (2,001 current, 526 non-current).
• Cash and cash equivalents: INR 18 Mn.

Strategic Priorities & Outlook

• Focus on margin expansion and raw-material efficiency.
• Capex and capacity utilization improvements to sustain growth.
• Maintain operating leverage to support profitability.

ESOP grant details

• NRC approved grant of 18,000 ESOPs under the ESOP Scheme 2022.
• Exercise price fixed at Rs 10 per option.
• Options exercisable for 3 years from vesting.
• Vesting details: currently no options vested.
• Total shares underlying: 18,000 equity shares.
• Options not yet exercised; no money realized.
• Conversion ratio: one option yields one share.
• Regulatory framework: SBEB Regulations 2021 compliance.
• Program administered by NRC; subject to eligibility criteria.
• Diluted EPS impact pending upon exercise.